The BNF provides UK healthcare professionals with authoritative and practical information on the selection and clinical use of medicines in a clear, concise and accessible manner.
The UK Clinical Pharmacy Association (UKCPA) is a not-for-profit member organisation for pharmacists, technicians and health care professionals who provide clinical pharmacy services to patients. It promotes expert practice in medicines management and strives to foster and support excellence, leadership and partnership in clinical pharmacy practice in order for practitioners to provide outstanding patient care
Drug Safety is the premier international journal covering the disciplines of pharmacovigilance, pharmacoepidemiology, benefit-risk assessment and risk management. The journal specializes in definitive reviews on the epidemiology, clinical features, prevention and management of adverse effects of individual drugs and drug classes. High-quality original research focusing on the clinical implications of drug treatment safety issues is also published.
The EMA began in 1995 as a new European system for the authorisation of medicinal products. The principal scientific bodies of the EMA are the Committee for Medicinal Products for Human Use (CHMP), the Committee for Veterinary Medicinal Products (CVMP), and the Committee for Herbal Medicinal Products (HMPC).
The Faculty of Pharmaceutical Medicine (FPM) is a professional membership organisation with over 1,500 members. They are a standard-setting body that is primarily concerned with raising standards in pharmaceutical medicine for the benefit of the public. The FPM run Pharmaceutical Medicine Specialty Training to equip physicians with specialist knowledge and comprehensive skills and competencies to practice to the highest ethical and professional standards, for the benefit and safety of patients and the public, in the development and maintenance of medicines.The DSRU works with the Faculty of Pharmaceutical Medicine to deliver the Drug Safety Surveillance module of Pharmaceutical Medicine Speciality Training
ISoP is concerned with the clinical dimensions of pharmacovigilance and provides a forum to raise the profile and influence of science between all major partners while aiming to assist health professionals recognise their identity as pharmacovigilance practitioners.
The Executive Agency of the Department of Health protecting and promoting public health and patient safety by ensuring that medicines, healthcare products and medical equipment meet appropriate standards of safety, quality, performance and effectiveness, and are used safely.
PIPA is the professional organisation for individuals in the pharmaceutical industry involved in the provision and management of information. The association was formed in 1974 and was previously known as AIOPI (Association of Information Officers in the Pharmaceutical Industry).
2nd – 3rd October 2019 at Stratford Manor Hotel.
To view the agenda please visit: https://www.pipaonline.org/Conference-Programme-2019
To book your place please visit: https://www.pipaonline.org/Events/PIPA-Conference-2019-Delegates/64529
The Faculty of Science at the University of Portsmouth has a longstanding and well-deserved reputation for excellence in both research and teaching. The School of Pharmacy and Biomedical Sciences, within the Faculty of Science, are a collaborative partner for the DSRU’s postgraduate programme in Pharmacovigilance.
NHS Business Services Authority remunerate and reimburse dispensing contractors across England. They also provide the NHS with a range of financial, drug and prescribing information.
A source of clinical knowledge about the common conditions generally managed in primary and first contact care, which has been designed to be used by healthcare professionals together with patients.
A non-profit organisation which provides a forum for regular discussion of statistics and issues relating to the practice of statistics in the pharmaceutical industry.
The main purpose and activity of the UMC is the collection of data about Adverse Drug Reactions from the worldwide community, especially from countries who are members of the WHO International Drug Monitoring Programme, their role is to generate safety signals for drugs which might possibly have problematic side-effects.